

Attorney Docket No. 009848-0356193
Client Reference: K1577 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ERICH E. WANKER, SABINE ENGEMANN, SUSANNE RAUTENBERG,
ANNETT BOEDDRICH, PHOEBE HARJAS, DAGMAR LITSCHER,
MARTIN HERBST, and Jacqueline WALTHER

Application No.:	To be assigned	Confirmation No:	TBA
Filed:	August 10, 2006	Group No.:	TBA
For:	NOVEL PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES	Examiner	To be assigned

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

APPLICATION DATA SHEET
37 C.F.R. § 1.76

BIBLIOGRAPHIC DATA

1. Applicant information

First applicant: ERICH WANKER
Citizenship: Austrian
Residence: Wolfshagener Str. 85, 13187 Berlin, Germany

Second applicant: SABINE ENGEMANN
Citizenship: German
Residence: Flughafenstr. 22, 12053 Berlin, Germany

Third applicant: SUSANNE RAUTENBERG
Citizenship: German
Residence: Reulestr. 1, 12105 Berlin, Germany

Fourth applicant: ANNETT BOEDDRICH
Citizenship: German
Residence: Friedrich-Ludwig-Jahn-Str. 68, 14612 Falkensee, Germany

Fifth applicant: PHOEBE HARJES
Citizenship: German
Residence: Busonistr. 92, 13125 Berlin, Germany

Sixth applicant: DAGMAR LITSCHER
Citizenship: Austrian
Residence: Steegerstr. 71, 13359 Berlin, Germany

Seventh applicant: MARTIN HERBST
Citizenship: German
Residence: Ackerstr. 1, 10115 Berlin, Germany

Eighth applicant: Jacqueline WALTHER
Citizenship: German
Residence: Heinersdorfer Str. 36, 14513 Teltow, Germany

2. Correspondence information

Correspondence for this application should be addressed as follows:

Customer No.: 27500

3. Application information

Title of Invention: NOVEL PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES

Docket number assigned to this application: 009848-0356193

Suggested Classification: Class:

Subclass:

Technology Center to which subject matter is assigned:

Total number of drawing sheets: 36

Type of application: Utility (National Phase Entry)

Application is to be published. Suggested drawing figure for publication: 1

Secrecy order under § 5.2:

This application does not disclose subject matter of an application which is under a secrecy order pursuant to § 5.2.

4. Representative information

The following have a power of attorney or authorization of agent in this application:

Customer No.: 27500

5. Foreign priority information

Foreign priority is claimed for this application as follows:

Country: WO

Application No.: PCT/EP2005/001389

Filing Date: February 11, 2005

Status: Pending

Country: Germany

Application No.: 10 2004 007 384.8

Filing Date: February 11, 2004

Status: Pending

6. Assignee information


The assignee(s) of this application is/are:

Max-Delbrück-Centrum Für Molekulare Medizin
Robert-Rössle-Str. 10
13125 Berlin,
Germany

Extent of interest of assignee in application: Entire rights, title and interest.

Date: August 10, 2006

PILLSBURY WINTHROP SHAW PITTMAN LLP
11682 El Camino Real
Suite 200
San Diego, CA 92130-2092
Customer No. 27500



Signature of Practitioner
John R. Wetherell
Registration No. 31,678
(858) 509-4022

CERTIFICATION UNDER 37 C.F.R. §§ 1.8 and/or 1.10*

(When using Express Mail, the Express Mail label number is *mandatory*; Express Mail certification is *optional*.)

I hereby certify that, on the date shown below, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee", Mailing Label No. EV 632470948 US, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: August 10, 2006



Signature

PATRICIA MUNOZ

(type or print name of person certifying)

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.